# Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition

> **NCT07468604** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 78 (estimated)

## Conditions studied

- Autonomic Dysfunction

## Interventions

- **DRUG:** 5 mL of 0.25% bupivacaine with epinephrine (1:200,000)
- **OTHER:** Sham Group

## Key facts

- **NCT ID:** NCT07468604
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468604, "Cervicothoracic Sympathetic Block Evaluation for Post COVID Condition". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07468604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*